EFG
RXRX icon

Ethos Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Ethos Financial Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72.1K Buy
23,486
+10,466
+80% +$40.4K 0.01% 525
2025
Q4 		$53.3K Buy
+13,020
New +$64.5K ﹤0.01% 515

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ethos Financial Group's RXRX Position: Q1 2026 in Review

Ethos Financial Group increased its Recursion Pharmaceuticals (RXRX) stake by 80% in Q1 2026, buying an estimated $40.4K and bringing the position to 23,486 shares worth $72.1K. The position accounts for 0.01% of the portfolio, ranked #525.

Ethos Financial Group first reported a position in RXRX in Q4 2025 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Ethos Financial Group held 23,486 shares of Recursion Pharmaceuticals worth $72.1K as of Q1 2026.
  • Ethos Financial Group bought 10,466 Recursion Pharmaceuticals shares in Q1 2026, an estimated $40.4K.
  • Recursion Pharmaceuticals made up 0.01% of Ethos Financial Group's portfolio in Q1 2026, its #525 holding.
  • Ethos Financial Group first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Ethos Financial Group's 13F filing for Q1 2026, filed 5 May 2026.